Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

64.41
-0.2800-0.43%
Pre-market: 64.40-0.0100-0.02%08:39 EDT
Volume:6.57M
Turnover:423.82M
Market Cap:131.12B
PE:14.18
High:65.05
Open:64.57
Low:64.26
Close:64.69
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.93
T/O Rate:0.32%
Dividend:2.51
Dividend Rate:3.90%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.87
PE(LYR):18.62

Loading ...

Bloomsbury Executives Adjust Holdings After 2023 Share Plan Vesting

TIPRANKS
·
1 hour ago

HSBC Adjusts Price Target on Bristol-Myers Squibb to $65 From $60, Keeps Hold Rating

MT Newswires Live
·
3 hours ago

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY), Stryker (SYK) and InnovAge Holding (INNV)

TIPRANKS
·
Yesterday

CD&R Appoints Novartis Chair Giovanni Caforio Operating Advisor to Funds

Reuters
·
Yesterday

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.25% on Sep 8: Facts Behind the Movement

TradingKey
·
Yesterday

Movement Alert|Bristol-Myers Squibb Falls 3.05% in Regular Trading, CAR-T Safety Concerns Across Sector Offset Positive Clinical Data

Market Focus
·
Sep 08

Bristol Myers Squibb's Phase 2 Study of Arlocabtagene Autoleucel Meets Key Endpoints

MT Newswires Live
·
Sep 08

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

TIPRANKS
·
Sep 08

Bristol Myers Squibb's Therapy Meets Mid-Stage Trial Goal

Reuters
·
Sep 08

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 Quintessential Trial of the Potential First-in-Class Gprc5d-Directed Car T Cell Therapy, Arlocabtagene Autoleucel ...

THOMSON REUTERS
·
Sep 08

Bristol-Myers Squibb Company - Phase 2 Trial Met Primary Endpoint of Overall Response Rate and Complete Response Rate

THOMSON REUTERS
·
Sep 08

Bristol-Myers Squibb Company - Arlo-Cel Safety Profile Consistent with Other Car T Cell Therapies

THOMSON REUTERS
·
Sep 08

Jeito Capital Promotes Pascal Touchon to Partner

Reuters
·
Sep 08

Berenberg Bank Sticks to Its Buy Rating for Bloomsbury Publishing (BMY)

TIPRANKS
·
Sep 08

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial

TIPRANKS
·
Sep 05

Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects

Dow Jones
·
Sep 04

Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns

MT Newswires Live
·
Sep 04